SLAS Discovery

Scope & Guideline

Catalyzing Scientific Progress in Life Sciences

Introduction

Delve into the academic richness of SLAS Discovery with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2472-5552
PublisherELSEVIER SCIENCE INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2017 to 2024
AbbreviationSLAS DISCOV / SLAS Discov.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

SLAS Discovery focuses on innovative methodologies and technologies that drive drug discovery and development, particularly emphasizing high-throughput screening (HTS) and its applications across various therapeutic areas.
  1. High-Throughput Screening (HTS):
    The journal extensively covers the development and optimization of high-throughput screening methodologies for drug discovery, enabling rapid evaluation of large compound libraries against biological targets.
  2. Cell-Based Assays and Imaging:
    SLAS Discovery emphasizes the use of cell-based assays, including high-content imaging and 3D cell cultures, to better mimic in vivo conditions and enhance the relevance of screening results.
  3. Target Identification and Validation:
    Research published in the journal often focuses on novel strategies for target identification and validation, including the application of proteomics and genomics to discover new drug targets.
  4. Automation and Robotics in Drug Discovery:
    The journal highlights advancements in automation and robotics that facilitate efficient assay development and compound screening, improving reproducibility and data quality in drug discovery.
  5. Phenotypic Screening:
    SLAS Discovery also explores phenotypic screening approaches that assess biological responses to compounds in cellular models, offering insights into complex drug action mechanisms.
  6. Emerging Technologies:
    The journal is dedicated to showcasing emerging technologies such as artificial intelligence (AI) and machine learning (ML) in drug discovery, aiming to enhance data analysis and predictive capabilities.
The landscape of drug discovery is rapidly changing, and SLAS Discovery reflects this evolution through an increasing focus on several key emerging themes.
  1. COVID-19 Therapeutics:
    A significant number of recent publications are dedicated to discovering and validating therapeutics for COVID-19, reflecting the urgent need for effective treatments and the journal's responsiveness to global health challenges.
  2. 3D Cell Culture and Organoids:
    There is a growing trend towards the use of 3D cell culture systems and organoids, which provide more accurate representations of human tissues, enhancing drug screening and development processes.
  3. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning techniques into drug discovery processes is on the rise, with studies focusing on data mining, predictive modeling, and automated analysis to streamline hit identification.
  4. Targeted Protein Degradation:
    Research on targeted protein degradation, particularly using PROTACs (Proteolysis Targeting Chimeras), is emerging as a significant area of interest, offering new strategies for drug discovery against challenging targets.
  5. Synergistic Drug Combinations:
    There is an increasing focus on identifying synergistic drug combinations to enhance therapeutic efficacy, particularly in cancer treatment, which reflects a shift towards personalized medicine approaches.

Declining or Waning

While SLAS Discovery continues to evolve, certain themes are becoming less prominent in recent publications, indicating a shift in focus within the field.
  1. Traditional Biochemical Assays:
    There is a noticeable decline in publications focusing solely on traditional biochemical assays, as the field moves towards more complex and physiologically relevant models.
  2. Single-Dimensional Drug Screening:
    Research centered around single-dimensional drug screening methods is waning, with a shift towards more integrated and multi-parametric approaches that provide a broader understanding of drug effects.
  3. Basic Pharmacology Studies:
    Basic pharmacology studies that do not incorporate advanced technologies or high-throughput capabilities appear to be less frequent, as there is a growing emphasis on translational research and clinical relevance.
  4. In Vitro Models Lacking Complexity:
    The use of simplistic in vitro models is decreasing, as researchers prioritize more complex systems that better replicate human physiology, such as organoids and multi-cellular models.
  5. Focus on Established Targets:
    There is a reduction in studies targeting well-characterized pathways or proteins, as the field increasingly seeks novel targets and mechanisms of action to overcome drug resistance.

Similar Journals

Current Bioinformatics

Advancing the Frontiers of Bioinformatics Research
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8936Frequency: 6 issues/year

Current Bioinformatics, an esteemed journal published by Bentham Science Publishers Ltd, serves as a pivotal platform for the dissemination of cutting-edge research in the fields of bioinformatics, biochemistry, computational mathematics, genetics, and molecular biology. With an ISSN of 1574-8936 and an E-ISSN of 2212-392X, this journal has established itself as a vital resource for researchers, professionals, and students keen on exploring interdisciplinary approaches to biological data analysis. Its prominence is reflected in its quartile rankings for 2023, where it stands in Q3 for biochemistry and computational mathematics, alongside Q4 rankings in genetics and molecular biology. Current Bioinformatics, located in the United Arab Emirates and converging from 2007 to 2024, aims to foster innovation in the field by presenting original research articles, reviews, and case studies that drive forward our understanding of complex biological systems through computational techniques. This journal is an integral resource for those wishing to stay at the forefront of bioinformatics research and applications.

Expert Opinion on Drug Discovery

Advancing Knowledge in Drug Discovery
Publisher: TAYLOR & FRANCIS LTDISSN: 1746-0441Frequency: 6 issues/year

Expert Opinion on Drug Discovery, published by Taylor & Francis Ltd, is a premier journal dedicated to the rapidly evolving field of drug development and innovation. With a strong emphasis on the integration of multidisciplinary approaches in pharmacology and toxicology, the journal has established itself as an invaluable resource for researchers, professionals, and students alike. Its impressive impact factor and classification as a Q1 journal in drug discovery, alongside its high Scopus ranking (Rank #20/157, Percentile 87th), underscore its significance within the academic community. Spanning from 2006 to 2024, Expert Opinion on Drug Discovery features a wide range of expert reviews and opinion articles that provide insights into the latest trends and breakthroughs in drug discovery, fostering collaboration and knowledge exchange. While the journal is not open access, it plays a critical role in shaping the future of drug development, making it an essential platform for those seeking to deepen their understanding of this dynamic field.

Drug Metabolism and Pharmacokinetics

Pioneering Research in Drug Metabolism and Pharmacokinetics
Publisher: JAPANESE SOC STUDY XENOBIOTICSISSN: 1347-4367Frequency: 6 issues/year

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.

MOLECULAR & CELLULAR PROTEOMICS

Innovating the future of molecular and cellular studies.
Publisher: ELSEVIERISSN: Frequency: 1 issue/year

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

Drug Target Insights

Advancing the Future of Pharmacology and Drug Discovery.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

DRUG DISCOVERY TODAY

Pioneering Insights in Pharmacology and Drug Development
Publisher: ELSEVIER SCI LTDISSN: 1359-6446Frequency: 12 issues/year

DRUG DISCOVERY TODAY is a premier journal published by Elsevier Science Ltd, providing a vital platform for researchers, professionals, and students dedicated to the fields of drug discovery and pharmacology. With the ISSN 1359-6446 and E-ISSN 1878-5832, this esteemed journal has positioned itself at the forefront of scientific literature since its inception in 1996, boasting an impressive convergence set to last until 2024. Recognized for its rigorous peer-review process and high-quality publications, DRUG DISCOVERY TODAY attained a prestigious Q1 ranking in both Drug Discovery and Pharmacology categories for 2023, reflecting its significant impact and relevance in the field. With Scopus rankings placing it within the top percentile, at ranks #9 in Drug Discovery and #17 in Pharmacology out of over 300 journals, this journal serves as a crucial resource for the latest advancements and innovations in drug development. Although it does not offer Open Access, its comprehensive scope encompasses the most recent research, reviews, and insights, making DRUG DISCOVERY TODAY an essential read for anyone seeking to advance their knowledge and practice in pharmaceutical sciences.

Digital Discovery

Connecting Researchers in the Evolving Landscape of Digital Science
Publisher: ROYAL SOC CHEMISTRYISSN: Frequency: 6 issues/year

Digital Discovery is an innovative journal published by the Royal Society of Chemistry, specializing in the rapidly evolving field of digital chemistry and computational methods. Launched in 2022, this Open Access journal allows unrestricted access to cutting-edge research, which enhances the visibility and dissemination of scientific findings. With an impressive Q1 category ranking in Chemistry (miscellaneous) for 2023, Digital Discovery stands out as a pivotal platform for researchers looking to explore the intersections of digital innovation and chemical sciences. The journal is dedicated to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in this critical area of study, making it an essential resource for academics, industry professionals, and students alike. Readers can access all articles freely online, promoting a collaborative and inclusive academic community.

Advances in Pharmacological and Pharmaceutical Sciences

Bridging Research and Practice in Pharmaceutical Sciences.
Publisher: HINDAWI LTDISSN: 2633-4682Frequency: 1 issue/year

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

CELL BIOCHEMISTRY AND BIOPHYSICS

Catalyzing Discoveries in Cell Biochemistry and Biophysics
Publisher: HUMANA PRESS INCISSN: 1085-9195Frequency: 4 issues/year

CELL BIOCHEMISTRY AND BIOPHYSICS is a distinguished journal published by HUMANA PRESS INC, focusing on critical advancements in the fields of biochemistry, biophysics, and cell biology. Since its establishment, the journal has provided a robust platform for the dissemination of cutting-edge research, covering diverse aspects of cellular biochemistry and the physical principles that underlie biological systems. With an emphasis on interdisciplinary studies, the journal aims to facilitate knowledge exchange among researchers, professionals, and students from various scientific backgrounds. As reflected in its 2023 category rankings, it holds a respectable position in Q3 for Biochemistry and Cell Biology, and Q2 for both Biophysics and Medicine (miscellaneous), indicating its significant contribution to these fields. Although it operates under a subscription model, the journal's commitment to maintaining high publication standards ensures that only impactful studies are shared with its audience. With a range of articles spanning theoretical insights to practical applications, CELL BIOCHEMISTRY AND BIOPHYSICS is an essential resource for those aiming to stay at the forefront of biochemical and biophysical research.

NATURE REVIEWS DRUG DISCOVERY

Shaping the future of therapeutic advancements.
Publisher: NATURE PORTFOLIOISSN: 1474-1776Frequency: 12 issues/year

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.